Prof Hang Quach
Honorary Clinical Professor
Department of Medicine
551 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
DOI: 10.1038/s41408-025-01436-02026
Journal article
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
DOI: 10.1016/S0140-6736(26)01088-32026
Journal article
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba75062026
Journal article
Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.
DOI: 10.1200/jco.2026.44.16_suppl.75652026
Journal article
MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).
DOI: 10.1200/jco.2026.44.16_suppl.75072026
Journal article
DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).
DOI: 10.1200/jco.2026.44.16_suppl.75032018
Research grants (other domestic)
Novel Immunotherapy Approach for Rescuing Inadequate Responses and Resistance to Treatment for Patients With Multiple Myeloma
RECENT SCHOLARLY WORKS
2026
Journal article
Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
DOI: 10.1200/jco.2026.44.16_suppl.75152026
Journal article
Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.
DOI: 10.1200/jco.2026.44.16_suppl.75632026
Journal article
Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
DOI: 10.1200/jco.2026.44.16_suppl.75642026
Journal article
Circulating tumor DNA NRAS and TP53 mutations to identify ultra-high-risk primary refractory myeloma patients.
DOI: 10.1200/jco.2026.44.16_suppl.7557
RECENT PROJECTS
2018
Research grants (other domestic)
Novel Immunotherapy Approach for Rescuing Inadequate Responses and Resistance to Treatment for Patients With Multiple Myeloma
2014
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma
2013
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma